Breast cancer is still the most common cancer in women worldwide. Resistance to drugs and recurrence of the disease are two leading causes of failure in treatment. For a more efficient treatment of patients, the development of novel therapeutic regimes is needed. Recent studies indicate that modulation of autophagy in concert with apoptosis induction may provide a promising novel strategy in breast cancer treatment. Apoptosis and autophagy are two tightly regulated distinct cellular processes. To maintain tissue homeostasis abnormal cells are disposed largely by means of apoptosis. Autophagy, however, contributes to tissue homeostasis and cell fitness by scavenging of damaged organelles, lipids, proteins, and DNA. Defects in autophagy promote tumorigenesis, whereas upon tumor formation rapidly proliferating cancer cells may rely on autophagy to survive. Given that evasion of apoptosis is one of the characteristic hallmarks of cancer cells, inhibiting autophagy and promoting apoptosis can negatively influence cancer cell survival and increase cell death. Hence, combination of antiautophagic agents with the enhancement of apoptosis may restore apoptosis and provide a therapeutic advantage against breast cancer. In this review, we discuss the cross-talk of autophagy and apoptosis and the diverse facets of autophagy in breast cancer cells leading to novel models for more effective therapeutic strategies.
Skip Nav Destination
Article navigation
July 2022
-
Cover Image
Cover Image
The cover image shows the double hexameric ring structures of Mycobacterium tuberculosis EccCb1 in apo and EsxAB+ATP+Mg2+ bound forms. The binding affinity EsxAB substrate to EccCb1 is enhanced ~2-fold in presence of ATP and Mg2+, which indicate the involvement of ATPase activity in EsxAB substrate translocation. Read more from Saxena and colleagues on pages 1559–1579
Review Article|
July 29 2022
The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?
In Collection
Cell death and survival
Kamil Seyrek;
Kamil Seyrek
Writing - review & editing
Translational Inflammation Research, Medical Faculty, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany
Search for other works by this author on:
Fabian Wohlfromm;
Fabian Wohlfromm
Writing - review & editing
Translational Inflammation Research, Medical Faculty, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany
Search for other works by this author on:
Johannes Espe;
Johannes Espe
Writing - review & editing
Translational Inflammation Research, Medical Faculty, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany
Search for other works by this author on:
Inna N. Lavrik
Translational Inflammation Research, Medical Faculty, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany
Correspondence: Inna N. Lavrik (inna.lavrik@med.ovgu.de)
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
December 19 2021
Revision Received:
July 05 2022
Accepted:
July 06 2022
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2022
Biochem J (2022) 479 (14): 1581–1608.
Article history
Received:
December 19 2021
Revision Received:
July 05 2022
Accepted:
July 06 2022
Citation
Kamil Seyrek, Fabian Wohlfromm, Johannes Espe, Inna N. Lavrik; The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?. Biochem J 29 July 2022; 479 (14): 1581–1608. doi: https://doi.org/10.1042/BCJ20210676
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.